{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:23:43Z","timestamp":1790126623029,"version":"4.0.1"},"reference-count":43,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>As new SARS-CoV-2 variants continue to emerge, it is important to evaluate the potency of antiviral drugs to support their continued use. Remdesivir (RDV; VEKLURY\u00ae) an approved antiviral treatment for COVID-19, and obeldesivir (ODV) are inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase Nsp12. Here we show these two compounds retain antiviral activity against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, JN.1.7, JN.1.18, KP.2, KP.3, LB.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF when compared with reference strains. Genomic analysis identified 29 Nsp12 polymorphisms in these and previous Omicron variants. Phenotypic analysis of these polymorphisms confirmed no impact on the antiviral activity of RDV or ODV and suggests Omicron variants containing these Nsp12 polymorphisms remain susceptible to both compounds. These data support the continued use of RDV in the context of circulating SARS-CoV-2 variants and the development of ODV as an antiviral therapeutic.<\/jats:p>","DOI":"10.3390\/v17020168","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T04:59:10Z","timestamp":1737953950000},"page":"168","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants"],"prefix":"10.3390","volume":"17","author":[{"given":"Lauren","family":"Rodriguez","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Lizbeth Reyes","family":"Zamora","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Han","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Moshiri","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Peinovich","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Martinez","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Yan","family":"Ho","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Li","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aeschbacher","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-1761","authenticated-orcid":false,"given":"Andrew","family":"Pekosz","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-1727","authenticated-orcid":false,"given":"John P.","family":"Bilello","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Perry","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hedskog","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2023, July 07). Updated Working Definitions and Primary Actions for SARS-CoV-2 Variants. Available online: https:\/\/www.who.int\/publications\/m\/item\/updated-working-definitions-and-primary-actions-for--sars-cov-2-variants."},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2024, July 30). SARS-CoV-2 Variant Classifications and Definitions, Available online: https:\/\/stacks.cdc.gov\/view\/cdc\/10581."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team (2021). SARS-CoV-2 B.1.1.529 (Omicron) variant\u2014United States, December 1\u20138, 2021. MMWR Morb. Mortal. Wkly. Rep., 70, 1731\u20131734.","DOI":"10.15585\/mmwr.mm7050e1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.15585\/mmwr.mm7137a4","article-title":"Mortality risk among patients hospitalized primarily for COVID-19 during the Omicron and Delta variant pandemic periods\u2014United States, April 2020-June 2022","volume":"71","author":"Adjei","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (2023, November 20). COVID Data Tracker, Available online: https:\/\/covid.cdc.gov\/covid-data-tracker\/."},{"key":"ref_6","unstructured":"World Health Organization (2024, July 30). Tracking SARS-CoV-2 variants. Available online: https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/."},{"key":"ref_7","unstructured":"(2022). VEKLURY\u00ae (Remdesivir) [Prescribing Information], Gilead Sciences, Inc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"ofad500.574","DOI":"10.1093\/ofid\/ofad500.574","article-title":"505. Drug-drug interaction profiling of obeldesivir, a promising oral treatment for COVID-19","volume":"10","author":"Amini","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11701","DOI":"10.1021\/acs.jmedchem.3c00750","article-title":"Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys","volume":"66","author":"Mackman","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16156","DOI":"10.1074\/jbc.AC120.015720","article-title":"Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action","volume":"295","author":"Tchesnokov","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lo, M.K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A.L., Flint, M., McMullan, L.K., Siegel, D., and Clarke, M.O. (2017). GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci. Rep., 7.","DOI":"10.1038\/srep43395"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107940","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00221-18","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","article-title":"Prodrugs of a 1\u2032-CN-4-Aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the African green monkey model of RSV","volume":"64","author":"Mackman","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Radoshitzky, S.R., Iversen, P., Lu, X., Zou, J., Kaptein, S.J.F., Stuthman, K.S., Van Tongeren, S.A., Steffens, J., Gong, R., and Truong, H. (2023). Expanded profiling of remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-29517-9"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105329","DOI":"10.1016\/j.antiviral.2022.105329","article-title":"Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection","volume":"203","author":"Pitts","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/s41467-020-19055-7","article-title":"A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19","volume":"11","author":"Xie","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eadk6176","DOI":"10.1126\/science.adk6176","article-title":"Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus","volume":"383","author":"Cross","year":"2024","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"eadj4504","DOI":"10.1126\/scitranslmed.adj4504","article-title":"The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses","volume":"16","author":"Martinez","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Akerman, A., Milogiannakis, V., Jean, T., Esneau, C., Silva, M.R., Ison, T., Fichter, C., Lopez, J.A., Chandra, D., and Naing, Z. (2023). Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. EBioMedicine, 90.","DOI":"10.1016\/j.ebiom.2023.104545"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pochtovyi, A.A., Kustova, D.D., Siniavin, A.E., Dolzhikova, I.V., Shidlovskaya, E.V., Shpakova, O.G., Vasilchenko, L.A., Glavatskaya, A.A., Kuznetsova, N.A., and Iliukhina, A.A. (2023). In vitro efficacy of antivirals and monoclonal antibodies against SARS-CoV-2 Omicron lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1. Vaccines, 11.","DOI":"10.3390\/vaccines11101533"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"112443","DOI":"10.1016\/j.celrep.2023.112443","article-title":"Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants","volume":"42","author":"Qu","year":"2023","journal-title":"Cell Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-023-01391-x","article-title":"Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Patel, N., Trost, J.F., Guebre-Xabier, M., Zhou, H., Norton, J., Jiang, D., Cai, Z., Zhu, M., Marchese, A.M., and Greene, A.M. (2023). XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-46025-y"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.15585\/mmwr.mm7242e1","article-title":"Use of updated COVID-19 vaccines 2023-2024 formula for persons aged \u22656 months: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, September 2023","volume":"72","author":"Regan","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.15585\/mmwr.mm7316a4","article-title":"Use of an additional updated 2023-2024 COVID-19 vaccine dose for adults aged \u226565 years: Recommendations of the advisory committee on immunization practices\u2014United States, 2024","volume":"73","author":"Panagiotakopoulos","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2023.12.026","article-title":"Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants","volume":"187","author":"Qu","year":"2024","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","article-title":"Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure","volume":"24","author":"Yang","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","unstructured":"Infectious Diseases Society of America (2024, September 09). COVID-19 variant update\u20144 September 2024. Available online: https:\/\/www.idsociety.org\/covid-19-real-time-learning-network\/diagnostics\/covid-19-variant-update\/#\/+\/0\/publishedDate_na_dt\/desc\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S1473-3099(23)00813-7","article-title":"Virological characteristics of the SARS-CoV-2 JN.1 variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","unstructured":"US Food and Drug Administration (2024, September 09). Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/updated-covid-19-vaccines-use-united-states-beginning-fall-2024."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105153","DOI":"10.1016\/j.meegid.2021.105153","article-title":"Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations","volume":"97","author":"Showers","year":"2022","journal-title":"Infect. Genet. Evol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105033","DOI":"10.1016\/j.antiviral.2021.105033","article-title":"Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir","volume":"188","author":"Martin","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e0022222","DOI":"10.1128\/aac.00222-22","article-title":"Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants","volume":"66","author":"Pitts","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"104974","DOI":"10.1016\/j.antiviral.2020.104974","article-title":"A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2","volume":"185","author":"Zhang","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/infdis\/jiad270","article-title":"Viral resistance analyses from the remdesivir phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)","volume":"228","author":"Hedskog","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hedskog, C., Spinner, C.D., Protzer, U., Hoffmann, D., Ko, C., Gottlieb, R.L., Askar, M., Roestenberg, M., de Vries, J.J.C., and Carbo, E.C. (2024). No remdesivir resistance observed in the phase 3 severe and moderate COVID-19 SIMPLE trials. Viruses, 16.","DOI":"10.3390\/v16040546"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.cell.2020.07.033","article-title":"Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex","volume":"182","author":"Chen","year":"2020","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41586-022-05664-3","article-title":"Structural basis for substrate selection by the SARS-CoV-2 replicase","volume":"614","author":"Malone","year":"2023","journal-title":"Nature"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/168\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:35:58Z","timestamp":1759919758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["v17020168"],"URL":"https:\/\/doi.org\/10.3390\/v17020168","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]}}}